Skip to content
CMMBChemomab Therapeutics Ltd.

Earnings

When Chemomab Therapeutics Ltd. reports, what it reported each quarter, and how the stock took the results.

20 quarters. Mar 31, 2019 to Jun 30, 2025. mixed units.

Quarter by quarter

Q2 2025-$2.06MNo Q2 2024 on file

Latest results

  1. Q1 2023May 11, 2023, before the openThe release0.0%by the close of May 11
    Revenue
    —
    —
    Net income
    -$8.75M
    N/M
    EPS
    $0.04
    +81.8%
  2. Q4 2022Feb 21, 2023, before the openThe release+16.8%by the close of Feb 21
    Revenue
    —
    —
    Net income
    -$8.27M
    N/M
    EPS
    —
    —
  3. Q3 2022Nov 10, 2022, after the close1.0%by the close of Nov 11
    Revenue
    —
    —
    Net income
    -$8.08M
    N/M
    EPS
    $0.04
    +169.2%
  4. Q2 2022Aug 12, 2022, before the openThe release+14.3%by the close of Aug 12
    Revenue
    —
    —
    Net income
    -$6.19M
    N/M
    EPS
    $0.03
    +107.7%

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2025
Q2 2025Jun 30, 2025————————
FY 2024
Q2 2024Jun 30, 2024——————$0.01—
FY 2023
Q2 2023Jun 30, 2023——————$0.04—
Q1 2023Mar 31, 2023May 11, 2023 · pre-marketMay 11, 202341 d10-Q——$0.040.0%
Earlier years, FY 2019 to FY 2022

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QMay 11, 2023001807
10-KMar 20, 2023001041
10-QNov 10, 2022003931
10-QAug 12, 2022003074
10-QMay 12, 2022001919
10-KMar 30, 2022001304
10-QNov 12, 2021003509
10-QAug 13, 2021002696
10-QMay 13, 2021065588
10-KMar 9, 2021033822

Provenance

ProvenanceData status and checks

Chemomab Therapeutics Ltd. · CIK 1534248 · Engraved from SEC EDGAR